Adverse extracellular matrix (ECM) remodeling contributes to fibrotic disorders in the kidney, lung, and heart. Matrix metalloproteinases (MMPs) are key enzymes regulating ECM turnover, and MMP inhibition attenuates remodeling. Recent technological developments allow MMP-substrate relationships to be identified and explored as novel therapeutic targets. This review summarizes current and novel strategies to block MMP activity.
No takes yet. Share an insight, caveat, or question.
Merry L. Lindsey (2006) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: